1-[(4-Methoxyphenyl)methyl]-3-methylurea | 188911-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-[(4-Methoxyphenyl)methyl]-3-methylurea
• CAS: 188911-53-7
• 化学式: C₁₀H₁₄N₂O₂
• mdl: MFCD01332980
• 分子量: 194.233
• InChiKey: BVFWCUQJVZGIBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[(4-Methoxyphenyl)methyl]-3-methylurea 在 ammonium hydroxide 、 lithium aluminium tetrahydride 、 sodium dithionite 、 乙酸酐 、 potassium carbonate 、 对甲苯磺酸 、 溶剂黄146 、 sodium nitrite 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.67h， 生成 8-ethyl-7-(4-heptyl)-3-(4-methoxybenzyl)-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-one
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor₁ Receptor Antagonists

  摘要：

  A growing body of evidence suggests that CRF1, receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF, receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF, antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.

  DOI：

  10.1021/jm049787k
• 作为产物：
  描述：

  苄脲 在 titanium(IV) isopropylate 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 26.0h， 生成 1-[(4-Methoxyphenyl)methyl]-3-methylurea
  参考文献：
  名称：

  异丙醇钛（IV）和硼氢化钠的新型合成二取代脲

  摘要：

  本文介绍了异丙醇钛（IV）/硼氢化钠介导的芳香醛与单取代脲的酰胺化还原反应，高产率制备不对称二取代脲的方法。

  DOI：

  10.1016/s0040-4039(97)00149-4

文献信息

• HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
  申请人：GiraFpharma LLC

  公开号：US20190023666A1

  公开（公告）日：2019-01-24

  Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了氨基吡嗪化合物作为腺苷受体的调节剂。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• [EN] CYCLIC UREA DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'URÉE CYCLIQUE COMME ANTAGONISTES DES RÉCEPTEURS DES ANDROGÈNES
  申请人：NOVARTIS AG

  公开号：WO2013084138A1

  公开（公告）日：2013-06-13

  The present invention is directed to compounds of formula (I) wherein R1, R2, R3, and A are defined herein. The present invention also provides for pharmaceutical compositions comprising a compound of formula (I) as well as to the use of such compounds as androgen receptor antagonists for the treatment of diseases and conditions mediated by the androgen receptor, such as prostate cancer.

  本发明涉及式（I）中R1、R2、R3和A所定义的化合物。本发明还提供了包含式（I）化合物的药物组合物，以及将这些化合物用作雄激素受体拮抗剂治疗由雄激素受体介导的疾病和病况，如前列腺癌。
• Heterocyclic compounds as adenosine antagonists
  申请人：NUVATION BIO INC.

  公开号：US11028058B2

  公开（公告）日：2021-06-08

  Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了作为腺苷受体调节剂的氨基吡嗪化合物。这些化合物可用作治疗剂，用于治疗通过 G 蛋白偶联受体信号通路介导的疾病，尤其可用于肿瘤学。
• Methyl Pyruvate Oxime as a Carbonyl Synthon: Synthesis of Ureas, Carbamates, Thiocarbamates, and Anilides
  作者：Seo Yeon Kim、Hee Nam Lim

  DOI：10.1021/acs.orglett.4c01007

  日期：——

  strategy for the synthesis of unsymmetrical ureas, carbamates, thiocarbamates, and anilides was developed with methyl pyruvate oxime as the carbonyl synthon. The intrinsic reactivity of the reagent enabled consecutive disubstitution involving direct amidation and one-pot deoximative substitution with various nucleophiles. The utility of the method was demonstrated with the synthesis of bioactive molecules

  以丙酮酸甲酯肟为羰基合成子，开发了合成不对称脲、氨基甲酸酯、硫代氨基甲酸酯和苯胺的新策略。该试剂的固有反应性使得能够进行连续的取代，包括直接酰胺化和用各种亲核试剂进行一锅脱肟取代。该方法的实用性通过生物活性分子的合成得到了证明。
• ANTIVIRAL AGENTS AND USES THEREOF
  申请人：Griffith University

  公开号：EP3189050B1

  公开（公告）日：2020-02-05